Not only have other MSI2 fusions been detected in patient leukemia samples (i.e. PAX5-MSI2 [Wang et al., 2017], EVI1-MSI2 [De Weer et al., 2008], TTC40-MSI2 [Saleki et al., 2015]), but we have found that the MSI2 gene is also a frequent partner (in both the 3 prime and 5 prime locations) for an array of translocations in solid cancers, including breast, lung, and colon cancer (Jang et al., 2020; Supplementary file 1). This evidence concerns the gene PAX5 and leukemia.